Professor Raina MacIntyre (MBBS Hons 1, FRACP, FAFPHM, M App Epid, PhD) is NHMRC Leadership 3 Research Fellow and Professor of Global Biosecurity. She heads the Biosecurity Program at the Kirby Institute, which conducts research in epidemiology, vaccinology, bioterrorism prevention, mathematical modelling, genetic epidemiology, public health and clinical trials in infectious diseases and is an Adjunct Professor at ASU. As of the start of 2026, she is the #1 ranked researcher in the world on Respiratory Protective Devices, and in the top 20 for several other areas of infectious diseases (Expertscape). Her H index is 84/68 (GS/Scopus) with >35,000 citations (GS). FWCI 2.41 (2016-2026) & 24.5 for influenza surveillance, 10.52 for vaccine hesitancy; 853 policy cites in 40 countries in past 10 years (Scival Scopus Author ID: 7005082840). In 2023 and 2024 she was in Clarivate’s most highly cited in the world. She has 21.4% of her publications in the top 10% most cited papers (Scopus) in the past 5 years. Lancet Infectious Diseases published a profile of her in 2021 (VOL 21:4, P468, APRIL 01, 2021). Her home university, UNSW, is part of the PLUS Alliance between ASU, UNSW and Kings College London, and she has been working with ASU researchers since 2016.
Full profile: https://research.unsw.edu.au/people/professor-raina-macintyre
MBBS (1st class honours), University of Sydney 1988
Master's degree. Australian National University (ANU)
PhD Australian National University (ANU)
Research interests and full publication list available here:
https://research.unsw.edu.au/people/professor-raina-macintyre
Research lab: https://sphcm.med.unsw.edu.au/Raina-MacIntyre-research-lab
Professor Raina MacIntyre (MBBS Hons 1, FRACP, FAFPHM, M App Epid, PhD) is NHMRC Leadership 3 Fellow and Professor of Global Biosecurity. She heads the Biosecurity Program at the Kirby Institute, which conducts research in epidemiology, bioinformatics, health intelligence, vaccinology, bioterrorism prevention, mathematical modelling, genetic epidemiology, public health and clinical trials in infectious diseases. Her innovation, EPIWATCH®️, which she conceived and developed from 2016 onward is an advanced AI system for real-time global health intelligence. She is an innovator with a talent and vision for advanced health intelligence that can be applied in real-time to solve pressing problems. She has won many awards including the Eureka Prize for Leadership and Innovation in Science in 2022. As of the start of 2026, she was the #1 ranked researcher in the world on Respiratory Protective Devices and highly ranked in several other areas of infectious diseases (Expertscape). Her H index is 84/68 (GS/Scopus) with >35,000 citations. She was a Clarivate Top Cited Researcher in 2023 and 2024. In 2020 a quote from her invited editorial on masks was featured on the cover of Lancet (Vol 195 June 27 2020), reflecting her global recognition as an expert in masks. Lancet Infectious Diseases published a profile of her in 2021 (VOL 21:4, P468, APRIL 01, 2021).
Her research falls under 4 areas: Personal protective equipment, Vaccinology, Epidemic response and emerging infectious diseases, and bioterrorism prevention. She is a dual-specialist physician with training in epidemiology and modelling. Her research is underpinned by her clinical training, vaccine program experience, extensive field outbreak investigation and health intelligence/surveillance experience. She is on the WHO Technical Advisory Group on COVID-19 Vaccine Composition (TAG-CO-VAC 2021-2024), WHO SAGE ad-hoc Working Group on Smallpox and Mpox, and is the focal point for WHO GOARN in the UNSW GOARN member group.
She has led and developed an automated, real-time rapid epidemic intelligence platform, EPIWATCH®️, which uses AI to generate early epidemic signals from vast, global, open-source data. A Microsoft Accelerating Foundation Models Research Grant helped develop advanced AI for EPIWATCH®️. She funds and leads a team of analysts, epidemiologists, LLM/AI specialists and software engineers in EPIWATCH®️, a global hub of real-time epidemic detection, prevention and mitigation, with a suite of real-time decision support and risk analysis tools. Her vision for EPIWATCH®️ is to be a health intelligence service for global health protection and for public good. In 2024-25 she worked with US Indopacific Command on a WarGame, Able Resolve 2024 and 2025, which featured EPIWATCH®️.